Tirzepatide belongs to a class of medications called glucagon-like peptide-1 receptor agonist (GLP-1RA) and glucose-dependent insulinotropic polypeptide receptor agonist (GIPRA). Tirzepatide is designed to mimic the actions of the natural GLP-1 and GIP hormones in the body, which help regulate blood sugar levels. The unique aspect of Tirzepatide is that it combines the actions of both GLP-1 and GIP receptors, leading to more effective blood sugar control and potentially offering additional benefits such as weight loss. By activating these receptors, Tirzepatide promotes insulin secretion, suppresses glucagon (a hormone that raises blood sugar), slows down gastric emptying, and promotes satiety, which can help in managing diabetes and body weight. Studies have shown this dual action peptide has superior hyperglycemia control and reductions in Body Mass Index (BMI) to GLP-1 agonists (Semaglutide).

Semaglutide is a glucagon-like peptide that targets areas of the brain that regulate appetite and food intake. By mimicking Glucagon-Like Peptide-1 (GLP-1) in the body, semaglutide can increase insulin secretion and slow down gastric emptying—or, how fast your stomach empties food. This can suppress your appetite so you feel fuller longer, helping you eat less and lose weight in the process. It also helps improve insulin resistance which is a part of metabolic syndrome. This can happen over time due to inflammation, toxins and dysfunction. It is the key issue for many struggling with weight gain and resistant weight loss.

Semaglutide targets the GLP-1 receptor, while tirzepatide targets both GLP-1 and GIP receptors.